Cladribine

Drug #1893

Cladribine is a drug used to treat hairy cell leukemia,it is commonly referred to as 2CDA.It interferes with the growth of cancer cells and slows their growth and spread in the body.

← Previous drug Next drug →

Primary Characteristics

Cladribine is also known as 2-CdA, chlorodeoxyadenosine.

It is of Synthetic origin.

Molecular Weight: 285.69 · Solubility in Water: 6.35e+00g/l · Non-proprietary name: Cladribine.

Pharmacokinetics

Absorption: Cladribine has an oral bioavailability is 41% (±7%).

Distribution: Cladribine has a plasma protein binding is 20%.

Elimination: plasma half-life is 5.4 hours.

Indications

Cladribine is primarily indicated in conditions like Hairy cell leukaemia, Neutropenia, Thrombocythaemia.

Cladribine is also indicated for secondary conditions like Histiocytosis, Multiple sclerosis.

Contraindications

Cladribine is contraindicated in conditions like Hypersensitivity to any component of product.

Dosage

Cladribine's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.09 mg/kg/day	0.09 mg/kg/day	—	IV	Should be given for 7 consecutive days.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

3 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Cladribine in overdosage may give rise to further complications which include Bleeding , Dizziness .

The signs and symptoms that are produced after acute overdosage of Cladribine are Irreversible neurologic toxicity, Severe bone-marrow superssion, Thrombocytopenia , Anemia.

Cladribine is known to cause more or less tolerable side effects which are usually transient. These include Constipation , Headache, Loss of appetite, Nausea, Vomiting .

Warnings / Precautions

is a potent antineoplastic agent with potentially significant toxic side effects. It should be administered only under the supervision of a physician experienced with the use of cancer chemotherapeutic agents. Patients undergoing therapy should be closely observed for signs of hematologic and non-hematologic toxicity. Periodic assessment of peripheral blood counts, particularly during the first 4 to 8 weeks post-treatment, is recommended to detect the development of anemia, neutropenia and thrombocytopenia and for early detection of any potential sequelae (e.g., infection or bleeding).

Interference in Pathology

Cladribine may interfere in the diagnosis of Liver Function Test (LFT) .

Available Brands

None recorded.

Storage Conditions

Cladribine should be stored .

Drug Classification

1.8.2 — Cytotoxic (anti-neoplastic) drugs